TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 8B 16B 24B FY16: 21.9B FY17: 21.9B FY18: 18.3B FY19: 16.9B FY20: 16.7B FY21: 15.9B FY22: 14.9B FY23: 15.8B FY24: 16.5B FY25: 17.3B FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 4B 8B 12B FY16: 11.7B FY17: 10.6B FY18: 8.3B FY19: 7.5B FY20: 7.7B FY21: 7.6B FY22: 7B FY23: 7.6B FY24: 8.1B FY25: 8.9B FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Income Annual

-18B -12B -6B 0 6B 12B 18B FY16: 2.2B FY17: -17.5B FY18: -1.6B FY19: -443M FY20: -3.6B FY21: 1.7B FY22: -2.2B FY23: 433M FY24: -303M FY25: 2.2B FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Net Income Annual

-18B -12B -6B 0 6B 12B 18B FY16: 329M FY17: -16.3B FY18: -2.1B FY19: -999M FY20: -4B FY21: 417M FY22: -2.4B FY23: -559M FY24: -1.6B FY25: 1.4B FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 4B 8B 12B FY16: 10.2B FY17: 11.2B FY18: 10B FY19: 9.4B FY20: 8.9B FY21: 8.3B FY22: 8B FY23: 8.2B FY24: 8.5B FY25: 8.3B FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

0 1.5B 3B 4.5B FY16: 3.9B FY17: 2.2B FY18: 2.4B FY19: 748M FY20: 1.2B FY21: 798M FY22: 1.6B FY23: 1.4B FY24: 1.2B FY25: 1.6B FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

0 1.5B 3B 4.5B FY16: 3B FY17: 1.4B FY18: 1.8B FY19: 223M FY20: 638M FY21: 236M FY22: 1B FY23: 842M FY24: 749M FY25: 1.1B FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 400M 800M 1.2B FY16: 961 FY17: 1B FY18: 1B FY19: 1.1B FY20: 1.1B FY21: 1.1B FY22: 1.1B FY23: 1.1B FY24: 1.1B FY25: 1.2B FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q1 '15: 3.21 Q2 '15: 2.97 Q3 '15: 2.07 Q4 '15: 1.83 Q1 '16: 1.93 Q4 '16: 0.07 Q1 '17: 0.10 Q2 '17: -6.04 Q3 '17: -5.87 Q4 '17: -16.26 Q1 '18: -15.80 Q2 '18: -10.10 Q3 '18: -10.89 Q4 '18: -2.33 Q1 '19: -3.46 Q2 '19: -3.85 Q3 '19: -3.87 Q4 '19: -0.92 Q1 '20: -0.76 Q2 '20: 0.00 Q3 '20: -3.68 Q4 '20: -3.64 Q1 '21: -3.63 Q2 '21: -3.57 Q3 '21: 0.66 Q4 '22: -2.19 Q1 '23: -1.53 Q2 '23: -2.10 Q3 '23: -2.09 Q4 '23: -0.50 Q1 '24: -0.42 Q2 '24: -0.39 Q3 '24: -0.84 Q4 '24: -1.45 Q1 '25: -1.15 Q2 '25: -0.16 Q3 '25: 0.60 Q4 '25: 1.20 Q1 '26: 1.33 Q2 '26: 0.60 Q1 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.